DEFIANCE TRILLION DC IDX ETF (TRIL) Stock Price & Overview
NASDAQ:TRIL • US88636V8019
Current stock price
The current stock price of TRIL is 19.863 USD. Today TRIL is up by 0.29%. In the past month the price decreased by -2.68%.
TRIL Key Statistics
- Market Cap
- 2.083B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- N/A
- Dividend Yield
- N/A
TRIL Stock Performance
TRIL Stock Chart
TRIL Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to TRIL.
TRIL Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.11 | 373.296B | ||
| AMGN | AMGEN INC | 15.28 | 190.378B | ||
| GILD | GILEAD SCIENCES INC | 15.19 | 169.926B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.34 | 115.264B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.78 | 80.002B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.53 | 43.521B | ||
| INSM | INSMED INC | N/A | 31.815B | ||
| BIIB | BIOGEN INC | 11.43 | 28.04B | ||
| NTRA | NATERA INC | N/A | 27.8B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.5 | 23.341B | ||
| MRNA | MODERNA INC | N/A | 21.157B | ||
| EXAS | EXACT SCIENCES CORP | 345.14 | 20.026B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 18.471B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find more ETFs on the USA exchanges | Find stocks with similar TA and Setup ratings on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges
DEFIANCE TRILLION DC IDX ETF / TRIL FAQ
What does DEFIANCE TRILLION DC IDX ETF do?
Trillium Therapeutics, Inc. is a clinical stage immuno-oncology company, which engages in the research and development of therapies for the treatment of cancer. The company is headquartered in Mississauga, Ontario and currently employs 33 full-time employees. The company went IPO on 2005-01-11. The firm is engaged in developing therapies for the treatment of cancer. The firm is developing two clinical programs, TTI-621 and TTI-622, target CD47, a don’t eat me signal that blocks the ability of macrophages to phagocytose and destroy tumor cells. The TTI-621 is being evaluated in a multicenter, open-label phase I trial in patients with relapsed/refractory hematologic malignancies. The TTI-622 is Trillium’s second SIRPαFc fusion protein. TTI-622 consists of the same extracellular CD47-binding domain of human SIRPα as TTI-621 but has an immunoglobulin G4 (IgG4) Fc region instead of an IgG1 Fc. TTI-622 is being studied in a two-part, multicenter, open-label, phase Ia/Ib study in patients with advanced relapsed or refractory lymphoma or multiple myeloma (NCT03530683). The company focuses on developing inhibitors of CD47, a checkpoint of the innate immune system.
Can you provide the latest stock price for DEFIANCE TRILLION DC IDX ETF?
The current stock price of TRIL is 19.863 USD. The price increased by 0.29% in the last trading session.
How is the ChartMill rating for DEFIANCE TRILLION DC IDX ETF?
TRIL has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 0 out of 10.